Skip to Content
Morningstar

Bio-Techne Corp TECH

Morningstar Rating
Unlock
Stock XNAS Rating as of
$62.73 −1.28 (2.00%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
TECH is trading at a 19% discount.
Price
$62.35
Fair Value
$73.14
Uncertainty
High
1-Star Price
$892.61
5-Star Price
$95.27
Economic Moat
Mhrjrm
Capital Allocation
Lwrrzdn
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TECH is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$64.01
Day Range
$62.70–64.81
52-Week Range
$51.79–89.91
Bid/Ask
$61.40 / $74.00
Market Cap
$9.86 Bil
Volume/Avg
902,987 / 1.1 Mil

Key Statistics

Price/Earnings (Normalized)
33.18
Price/Sales
8.85
Dividend Yield (Trailing)
0.51%
Dividend Yield (Forward)
0.51%
Total Yield
1.32%

Company Profile

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Core
Total Number of Employees
3,050
Website
https://www.bio-techne.com

Comparables

Valuation

View More
Metric
TECH
TIHE
BIO
Price/Earnings (Normalized)
 33.18—24.44
Price/Book Value
 5.02—0.96
Price/Sales
 8.85—3.20
Price/Cash Flow
 30.89—10.59
Price/Earnings
TECH
TIHE
BIO

Financial Strength

Metric
TECH
TIHE
BIO
Quick Ratio
 2.54—4.01
Current Ratio
 4.37—5.83
Interest Coverage
 18.34—−18.24
Quick Ratio
TECH
TIHE
BIO

Profitability

Metric
TECH
TIHE
BIO
Return on Assets (Normalized)
 11.61%—2.73%
Return on Equity (Normalized)
 15.75%—3.84%
Return on Invested Capital (Normalized)
 13.09%—2.95%
Return on Assets
TECH
TIHE
BIO
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRNktfyjlxjFcc$553.3 Bil
VRTX
Vertex Pharmaceuticals IncMzpqhwzcTbghtt$101.6 Bil
REGN
Regeneron Pharmaceuticals IncYyzppjjmTdvhfl$98.9 Bil
MRNA
Moderna IncCrgtjzhxNkvl$39.7 Bil
ARGX
argenx SE ADRVbnbfgzxFdxw$22.1 Bil
BNTX
BioNTech SE ADRMlkdmtxlHpvj$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncGbywtqknyQcyrq$18.4 Bil
BMRN
Biomarin Pharmaceutical IncWptlmxmwCrfjb$17.2 Bil
RPRX
Royalty Pharma PLC Class AQhbgkggsmJjxphkm$12.3 Bil
INCY
Incyte CorpMjkzkxqnWjmzzsw$11.8 Bil

Sponsor Center